Sophie P. Syddall

Mechanism of Action and Preclinical Antitumor Activity of the Novel Hypoxia-Activated DNA Cross-Linking Agent PR-104

Adam V. Patterson, Dianne M. Ferry, Shelley J. Edmunds et al. · Clinical Cancer Research · 2007 · 247 citations · Full text

Medicine, Oncology, Pharmacology +16

Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A

Gareth A. Prosser, Janine N. Copp, Alexandra M. Mowday et al. · Biochemical Pharmacology · 2013 · 73 citations

Pharmacy, Biochemistry, Medicinal Chemistry +13

The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411NTR

Dean C. Singleton, D. Li, Sally Yan Bai et al. · Cancer Gene Therapy · 2007 · 55 citations

Medicine, Cancer Biology, Oncology +14

Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine <i>N</i> 3 DNA minor groove alkylators

William R. Wilson, Stephen M. Stribbling, Frederik B. Pruijn et al. · Molecular Cancer Therapeutics · 2009 · 34 citations

Medicine, Medicinal Chemistry, Pharmacology +15

<i>E. coli</i> nitroreductase NfsA is a reporter gene for non-invasive PET imaging in cancer gene therapy applications

Alexandra M. Mowday, Janine N. Copp, Sophie P. Syddall et al. · Theranostics · 2020 · 25 citations · Full text

Medicine, Molecular Biology, Nuclear Medicine +17